Literature DB >> 29451713

Glucose effectiveness is a critical pathogenic factor leading to glucose intolerance and type 2 diabetes: An ignored hypothesis.

F P Alford1,2, J E Henriksen3, C Rantzau2, H Beck-Nielsen3.   

Abstract

BACKGROUND: Although the ability of glucose to mediate its own in vivo metabolism is long documented, the quantitative measurement of whole body glucose-mediated glucose disposal at basal insulin levels (glucose effectiveness [GE]), followed the introduction of the Minimal Model intravenous glucose tolerance test technique.
METHODS: A literature review, combined with our own studies, of the role of GE in glucose metabolism in normal and "at risk" individuals, was undertaken to determine GE's contribution to glucose homeostasis.
RESULTS: GE accounts for ~45% to 65% of glucose disposal in man. A negative association between GE and insulin meditated glucose disposal (Si), is present in normal subjects without a family history of type 2 diabetes mellitus but is absent in normoglycaemic "at risk" relatives with a positive family history of diabetes mellitus. Intracellular GE disposal is mediated by mass action of glucose through the skeletal muscle membrane via facilitated Glut 4 transporters. However, GE is frequently forgotten as a significant contributor to the development of glucose intolerance in "at risk" individuals. Only limited studies have examined the role of a lower GE in such normoglycemic subjects with preexisting mild insulin resistance and β-cell dysfunction. These studies demonstrate that in "at risk" individuals, an initial low GE is a key contributor and predictor of future glucose intolerance, whereas an initial raised GE is protective against future glucose intolerance.
CONCLUSION: In "at risk" individuals, a low GE and genetically determined vulnerable β-cell function are more critical determinants of future glucose intolerance than their preexisting insulin-resistant state.
Copyright © 2018 John Wiley & Sons, Ltd.

Entities:  

Keywords:  beta cell function; glucose effectiveness; glucose intolerance; type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29451713     DOI: 10.1002/dmrr.2989

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  7 in total

Review 1.  Pathophysiology of type 2 diabetes in sub-Saharan Africans.

Authors:  Julia H Goedecke; Amy E Mendham
Journal:  Diabetologia       Date:  2022-09-27       Impact factor: 10.460

2.  Paternal bisphenol A exposure in mice impairs glucose tolerance in female offspring.

Authors:  Cetewayo S Rashid; Amita Bansal; Clementina Mesaros; Marisa S Bartolomei; Rebecca A Simmons
Journal:  Food Chem Toxicol       Date:  2020-09-03       Impact factor: 6.023

3.  An Analysis of Glucose Effectiveness in Subjects With or Without Type 2 Diabetes via Hierarchical Modeling.

Authors:  Shihao Hu; Yuzhi Lu; Andrea Tura; Giovanni Pacini; David Z D'Argenio
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-29       Impact factor: 5.555

4.  Vitamin B6 deficiency disrupts serotonin signaling in pancreatic islets and induces gestational diabetes in mice.

Authors:  Ashley M Fields; Kevin Welle; Elaine S Ho; Clementina Mesaros; Martha Susiarjo
Journal:  Commun Biol       Date:  2021-03-26

5.  Glucose Effectiveness from Short Insulin-Modified IVGTT and Its Application to the Study of Women with Previous Gestational Diabetes Mellitus.

Authors:  Micaela Morettini; Carlo Castriota; Christian Göbl; Alexandra Kautzky-Willer; Giovanni Pacini; Laura Burattini; Andrea Tura
Journal:  Diabetes Metab J       Date:  2020-01-13       Impact factor: 5.376

Review 6.  Glucose effectiveness: Lessons from studies on insulin-independent glucose clearance in mice.

Authors:  Bo Ahrén; Giovanni Pacini
Journal:  J Diabetes Investig       Date:  2020-12-01       Impact factor: 4.232

7.  Impact of Incretin Hormone Receptors on Insulin-Independent Glucose Disposal in Model Experiments in Mice.

Authors:  Tina Ovlund; Giovanni Pacini; Bo Ahrén
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-08       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.